Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2019

View Archived Issues

RUNX1 mRNA-containing nanomicelles prevent intervertebral disk degeneration in mice

BioCryst advancing factor D inhibitor BCX-9930 into clinic for complement-mediated diseases

Optogenetics helps understand TDP-43 aggregates

Tackling tendonitis

PIGU overexpression aids in the prognosis stratification of patients with HCC

CROI 2019: With additional long-term remission, number of possible HIV cures doubles to 2

Preliminary phase II data presented for RX-3117 in advanced urothelial cancer

RCN1 as a novel biomarker of prognosis in non-small cell lung cancer

PCDHGA7 downregulation in KRAS wild-type colorectal cancer is correlated with poor clinical outcomes

Ascendis Pharma presents results from phase III heiGHt trial for TransCon hGH

Nanoparticle MRI contrast agent SN-132D shows preclinical efficacy and safety

MyoKardia announces safety and efficacy data from PIONEER-OLE study of mavacamten

PsiOxus initiates first-in-human study of NG-350A

CARB-X funding to support Contrafect's development of amurins to treat Gram-negative pathogens

Principia Biopharma reports phase I data for PRN-2246

FORMA Therapeutics synthesizes new USP28 and USP25 inhibitors

University of Arizona discloses compounds for Parkinson's disease

Denali Therapeutics identifies EIF2B activators

Guangzhou Henovcom Bioscience describes ENPP2 inhibitors

Harvard College patent describes lincosamide antibiotics

BioXcel collaborates with Merck KGaA and Pfizer to study avelumab with BXCL-701 and NKTR-214

Akeso enrolling in phase Ib/II study of AK-104 for advanced solid tumors and gastric cancer

Grant funds IVI to provide support for typhoid conjugate vaccine studies

New phase Ib trial explores use of AVID-200 in diffuse cutaneous systemic sclerosis

FDA clears IND for phase I study of KO-539 in relapsed or refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...